PTPN6, a tyrosine phosphatase protein, plays a negative role in cell signal transduction and is negatively correlated with tumour formation and growth. However, epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia (CML) remains unclear. This study investigated bone marrow or blood samples from 44 CML patients and 10 healthy volunteers. KCL22 and K562 cells were cultured and treated with demethylation drugs and histone deacetylase inhibitors. Real time quantitative polymerase chain reaction (qPCR), methylation-specific PCR, bisulfite sequencing PCR, Western blotting, co-immunoprecipitation and chromatin immunoprecipitation (ChIP) was performed. PTPN6 was down-regulated in cell lines and patients with advanced phase CML, whereas DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 were up-regulated. Treatment with 5-azacytidine, decitabine, sodium valproate and LBH589 increased PTPN6 expression, but decreased that of DNMT1, DNMT3A, MECP2, MBD2 and HDAC1. Immunoprecipitation and mass spectrometry showed that HDAC1 combined directly with PTPN6. ChIP-seq showed that HDAC1 did not combine with the promoter region of PTPN6, while MAPK, AKT, STAT5, JAK2 and MYC promoter regions all combined with HDAC1. PTPN6 is associated with progression of CML. Low expression level of PTPN6 was associated with DNA methylation and regulated by histone acetylation. HDAC1 participates in the regulation of PTPN6.
Chronic myeloid leukaemia (CML) is a multiple malignant clonal disease of haematopoietic stem cells, the hallmark of which is the Philadelphia chromosome formation of the BCR/ABL1 fusion gene, encoding the P210 BCR/ABL1 protein. This tyrosine kinase signalling protein is involved in a series of continuous protein phosphorylation events that affect cell proliferation, differentiation, apoptosis and adhesion, resulting in the occurrence of CML. The natural course is divided into three phases: chronic (CP), accelerated (AP) and blast (BP). The accelerated and blast phases are considered to represent disease progression. CML development is a complex process with wide heterogeneity, involving many genetic and molecular biological events (Melo & Barnes, 2007) , and epigenetic regulation is the focus of recent research.
Epigenetic refers to a potentially heritable change in gene expression that does not involve a change in the genomic DNA sequence (Wolffe & Matzke, 1999) . Epigenetic changes mainly include: DNA methylation, histone modification, etc. PTPN6 (also termed SHP-1) is a recently discovered tumour suppressor gene that plays a negative regulatory role in signal transduction (Hsu et al, 2001) . It is involved in the regulation of cell growth, differentiation, metabolism, gene transcription and immune response and is negatively correlated with tumour formation and growth. Our previous study demonstrated that the expression levels of PTPN6 mRNA and PTPN6 protein were highest in CML-CP patients compared to CML-AP and CML-BP patients. In addition, we demonstrated that PTPN6 is related to the progression of CML, which is consistent with the results of other studies (Amin et al, 2007; Li et al, 2014) . Although the signalling downstream of PTPN6 regulation has been studied, the upstream regulation is poorly understood. Therefore, we aimed to explore the epigenetic regulation of PTPN6, to study the progression of CML.
Methods

Sample collection
Between September 2014 and October 2015, bone marrow or peripheral blood samples from 44 patients with CML were selected from the Department of Haematology at Hebei Medical University. Peripheral blood samples from 10 healthy volunteers were selected as controls (Table I) . Peripheral blood mononuclear cells were isolated by lymphocyte separation. This study was approved by the Ethics Committee of Hebei Medical University and written informed consent was obtained from each patient.
Inclusion criteria for this study included: (i) diagnosis of CML by bone marrow morphology, immunology, molecular biology and cytogenetics; (ii) clear pathological staging; (iii) availability of intact clinical data.
The exclusion criteria were: (i) significant organ dysfunction; (ii) pregnancy (in females); and (iii) did not sign the informed consent.
Cell culture KCL22 cells were purchased from Shanghai Hong Shun Biotechnology Co., Ltd. (Shanghai, China) and maintained in Iscove's modified Dulbecco's medium (IMDM; GIBCO, Beijing, China) supplemented with 10% fetal bovine serum (FBS) (Clark Bio, Claymont, DE, USA), 100 units/ml penicillin and 100 lg/ml streptomycin. K562 cells (retained in our laboratory) were maintained in RPMI 1640 medium (GIBCO) containing 10% FBS and penicillin/streptomycin. 
Real-time polymerase chain reaction
Total RNA was isolated with the RNA easy mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions and reverse transcribed using Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (Invitrogen, Carlsbad, CA, USA), the reaction was performed at 25°C for 5 min, 42°C for 60 min and 70°C for 5 min. Polymerase chain reaction (PCR) amplification was performed in 20-ll final volumes containing 1 ll of template cDNA, 1 ll of each respective primer, 10 ll SuperMix-UDG qPCR and 7 ll of diethyl pyrocarbonate (DEPC) treated water. All the amplifications were carried out in optical-grade 96-well plates on an ABI Prism 5700 sequence detection system (Applied Biosystems, Thermo Fisher Scientific, Shanghai, China) with an initial step at 95°C for 10 min followed by 40 cycles of 95°C for 15 s, 60°C for 1 min, and 72°C for 30 s. The C T (cycle threshold) was determined automatically by the instrument. Relative gene expression normalized to ACTB was determined via the 2 ÀDDCT formula. All experiments on gene (Table II) . (Oka et al, 2001) , and the original cDNA sequences were checked in the gene pool. The PCR products of the 2% agarose gel electrophoresis (GoldView; Saibaisheng Bioengineering Co., Ltd., Beijing, China) were as follows: PTPN6 methylated (M) and PTPN6 unmethylated (U) positive negative methylation; PTPN6 M and PTPN6 U partial methylation; and PTPN6 -1 M and PTPN6 U positive negative unmethylated. The primer was synthesised by Saibaisheng Bioengineering Co., Ltd. (Table III) .
Methylation-specific PCR
Bisulfite sequencing PCR
Bisulfite sequencing PCR (BSP) was performed to determine methylation of CpG islands. The CpG island of PTPN6 expression regulation area was predicted by Methprimer software (http://www.urogene.org/cgi-bin/methprime r/methprimer.cgi). The CpG islands were found across the promoter and the first exon region; the primers were designed with the region as the target sequence. The primers (Shanghai Generay Biotech Co. Ltd.) were: PTPN6 forward, 5 0 -AGGGTTGTGGTGAG-3 0 ; PTPN6 reverse, 5 0 -TTACA-CACTCCAAACCCAAATAATAC-3 0 ; with a product length of 222 bp (À1640 to À1861), which contains 11 CG sites. The extraction and detection steps of the genomic DNA were described above. The operation and purification kit was used for sulphite treatment of genomic DNA according to the manufacturer's instructions. The DNA PCR sulphite treatment using the above primers, was as follows: pre degeneration at 95°C for 4 min; modified 30 s at 94°C, at 55°C annealing for 30 s; an extension for 40 s at 72°C for 40 cycles, extending at 72°C for 5 min. The PCR products were resolved on 1% agarose gels, purified, and then ligated to the pTG19-T vector. XL10-Gold (Shanghai Generay Biotech Co. Ltd.) was used for the transformation, recovery and coating of the product according to the manufacturer's instructions. The enzyme hydrolysis products identified as positive clones were sent for sequencing; 10 clones were selected for methylation sequencing.
Western blotting
Cells that had been treated differently were lysed in radioimmunoprecipitation assay (RIPA) buffer and protein samples were obtained. After quantification using the Bio-Rad DC protein assay kit II (Bio-Rad, Hercules, CA, USA), the protein samples were subjected to 8-15% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and electrotransferred onto a Hybond enhanced chemiluminescence (ECL) transfer membrane (Amersham Pharmacia, Piscataway, NJ, USA). After blocking with 5% non-fat skimmed milk, the membrane was probed with antibodies Gene Primer Products for DNMT1 (1:1000), DNMT3A (1:1000), DNMT3B
(1:1000), MECP2 (1:1000), MBD2 (1:1000), HDAC1
(1:1000), PTPN6 (1:1000), ACTB (1:5000) (Abcam, Cambridge, MA, USA) and exposed to horseradish peroxidase (HRP)-conjugated secondary anti-mouse or rabbit antibodies (1:5000, Qiao Yi Biotechnology, Hefei, China). Protein expression was examined using a BioSpectrum Imaging System (UVP, LLC, Upland, CA, USA).
Co-immunoprecipitation
Protein was extracted from cells with RIPA cell lysis buffer (Invitrogen) and quantified with the bicinchoninic acid assay. The interacting proteins were precipitated using a PTPN6 (SHP-1) antibody (Santa Cruz Biotechnology, Dallas, TX, USA), and SDS-PAGE was performed. The target protein was determined according to its position on the electrophoresis bands. The protein in the gel had a reductive alkylation reaction and was digested. The samples were analysed by Liquid Chromatography Coupled with Tandem Mass Spectrometry (LC and MS/MS), and the protein database was searched to identify the proteins in the immunoprecipitate. The biological function, signalling pathway and related diseases, which were related to the interaction of these proteins, were detected by MS after the interaction of the proteins. The INGENUITY â database (https://www.qiagenbioinf ormatics.com/products/ingenuity-pathway-analysis/) was used to conduct a comprehensive analysis of the biological function and role of the network access. Ingenuity â pathway analysis (IPA â ) software (http://www.ingenuity.com/produc ts/ipa) was introduced to analyse the biological function of the identified interacting proteins.
Chromatin immunoprecipitation
Cells were treated with formaldehyde and incubated for 10 min to generate DNA-protein cross-links. Cell lysates were then sonicated to generate chromatin fragments of 100-500 bp. HDAC1 antibody and beads were added to precipitate the DNA-protein complex. NaCl with the cross-linking solution at 65°C was used to obtain free DNA and protein.
A QIAGEN PCR kit was used to purify the DNA, and then chromatin immunoprecipitation (ChIP) and sequencing were performed. The raw reads of the output were filtered, including decontamination, de-sequencing of the adapters, and reads with a low mass base ratio, resulting in clean data.
Reads were aligned to the reference genome using the Short Oligonucleotide Analysis Package (SOAP) alignment software (http://soap.genomics.org.cn/soapaligner.html), and the reads of each library were de-duplicated as needed. Then, quality control was performed to determine whether the quality of the sequencing data reached the required standard. The unique alignment sequences obtained from the comparison were used to analyse both their coverage on the reference genome and the depth information of the genomic locus. The distribution of gene functional elements analysis, the function of the relevant genes significant enrichment analysis and pathway enrichment analysis was then performed.
Statistics
Data were presented as mean AE standard deviation (SD) of three replicates. One-way ANOVA and RxC contingency table chi-square test was applied by the statistical software SPSS 13.0 (SPSS Inc., Chicago, IL, USA). P values <0Á05 indicated a significant difference.
Results
Expression of mRNA and protein levels in CML patients
The expression level of DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 mRNA was higher in CML patients than normal controls (P < 0Á05), while the expression level of PTPN6mRNA was lower than normal controls (P < 0Á05). In addition, DNMT3B mRNA expression did not change significantly (P > 0Á05). DNMT1 mRNA expression was not significantly different between the CML stages (P > 0Á05). DNMT3A, MECP2, MBD2 and HDAC1 mRNA levels were highest in CML-BP (P < 0Á05). PTPN6 mRNA expression was similar in CML-AP and CML-BP (P < 0Á05) and significantly higher in CML-CP (P > 0Á05) ( Fig 1A) . DNMT1, DNMT3A, DNMT3B, MECP2, HDAC1, MBD2, and PTPN6 protein was detected in the bone marrow mononuclear cells of 10 patients with different stages of CML and healthy controls. Patients with CML had a lower expression level of DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 protein (P < 0Á05). In all patients with CML, DNMT1 expression level was not significantly different (P > 0Á05). DNMT3A, DNMT3B, MECP2, MBD2, HDAC1 and PTPN6 protein expression was highest in CML-BP patients (P < 0Á05). DNMT3B protein expression was similar in the CML patients and normal controls (P > 0Á05). PTPN6 protein expression was higher in normal and CML-CP patients compared to CML-AP and CML-BP, although this difference was not significant (P > 0Á05) (Fig 1B,C) .
Methylation status of the PTPN6 promoter in CML patients
The methylation status of the PTPN6 DNA promoter was detected by methylation-specific PCR (MSP) in the normal controls and CML patients. Methylation of the PTPN6 DNA promoter was not detected in the 10 normal controls, but was it methylated in 5 (25%) CML-CP patients and 24 CML patients with disease progression (14 CML-AP, 10 CML-BP). The frequency of methylation was significantly higher in patients with progressive disease compared with normal controls and CML-CP patients (P < 0Á01). Although methylation of the PTPN6 promoter occurred in the normal controls and CML-CP patients, this was not significantly different (P = 0Á14) (Fig 2) .
Determination of the half maximal effective concentration (EC 50 )
The EC 50 of decitabine, LBH589, 5-azacytidine and VPA was determined using the CCK-8 kit. The EC 50 of these drugs in K562 and KCL22 cells was, respectively, 13Á38 and CP-CML patients and normal control. *P < 0Á05 comparison among the four groups in each gene. #, D, ☆, ▲, P < 0Á05 compared with the other two groups. ★P < 0Á05 compared to the control and the CML-CP groups. ◆P < 0Á05 compared to the control and the CML-CP groups. ★ vs. ◆ P > 0Á05. AP, accelerated phase; BP, blast phase; CML, chronic myeloid leukaemia; CP, chronic phase; NC, normal controls.
9Á189 mmol/l for VPA; 6Á314 and 5Á485 nmol/l for LBH589; was 105Á2 and 303Á9 lmol/l for 5-azacytidine; and 37Á09 and 48Á08 lmol/l for decitabine (Fig 3) .
mRNA expression levels in CML blast cells after drug treatment
The concentration of each drug was determined by the EC50 prior to incubation with K562 cells and KCL22 cells. The concentrations used for VPA were 4, 8, and 12 mmol/l in K562 cells, and 2, 4 and 8 mmol/l in KCL22 cells. For LBH589, the concentrations used for both cell lines were 2, 2Á5 and 5 nmol/l. The concentrations of 5-azacytidine were 20, 40 and 80 lmol/l in K562, and 80, 160 and 320 lmol/l in KCL22. Decitabine was used at concentrations of 10, 20 and 40 lmol/l in both cell lines. It must be noted that the incubation time of decitabine was 24 h, whereas that of the other three drugs was 48 h.
Results showed that DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 mRNA expression decreased in a dose-dependent fashion. Minimum mRNA expression levels were seen when the maximum drug concentration was used (P < 0Á05). DNMT3B mRNA expression did not change significantly (P > 0Á05). The PTPN6 mRNA expression increased in a statistically significant dose-dependent manner (P < 0Á05) (Fig 4) .
Protein levels of the CML blast cell line after drug treatment
Cells in the high concentration drug groups were selected as the subject of this study according to the PCR results and the changes in protein expression were determined. Results showed that the expression level of DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 proteins decreased significantly (P < 0Á05), while that of DNMT3B was not significantly different (P > 0Á05). PTPN6 protein expression increased significantly (P < 0Á05). VPA and 5-azacytidine had a more obvious influence on cells than decitabine and LBH589 (Fig 5) .
Detection of PTPN6 promoter methylation in the drugtreated cells by MSP assay PTPN6 methylation was detected in K562 and KCL22 cells; no methylation of PTPN6 was detected after treatment with each of the four drugs in the untreated group (Fig 6) .
Detection of PTPN6 promoter methylation in the drugtreated cells by BSP assay
In K562 cells, the methylation rate of PTPN6 in the untreated group was 80Á9%. In the 12 mmol/l VPA treatment group, the methylation rate of CpG content was 56Á4% Fig 2. CpG methylation of the PTPN6 promoter from healthy controls and patients with CML. Methylation of the PTPN6 DNA promoter was not detected in normal controls. 25% of the CML-CP samples were methylated. All (100%) of the samples for patients with disease progression (CML-AP + CML-BP) were methylated rate compared with the normal controls and CML-CP patients, P < 0Á01. The methylation rate was not statistically different in the normal controls and the CML-CP patients (P = 0Á14). AP, accelerated phase; BP, blast phase; CML, chronic myeloid leukaemia; CP, chronic phase; M, methylated; NC, normal controls; U, unmethylated. compared with the untreated group at 48 h (P < 0Á05). In the 5 nmol/l LBH589 treatment group, the methylation rate of the CpG content was 80Á9% at 48 h. In the 80 lmol/l 5-azacytidine treatment group, the methylation rate of the CpG content was 78Á2% at 48 h. In the 40 lmol/l decitabine treatment group, the methylation rate of the CpG content was 81Á8% at 24 h. There was no significant difference between the three groups compared with the untreated group (P > 0Á05) (Fig 7A) .
In KCL22 cells, the methylation rate of PTPN6 in the untreated group was 85Á5%. In the 12 mmol/l VPA treatment cells, the methylation rate of the CpG content was 66Á4% compared with the untreated group at 48 h (P < 0Á05). In the 5 nmol/l LBH589 treatment group, the methylation rate of the CpG content was 82Á7% at 48 h. In the 320 lmol/l 5-azacytidine treatment group, the methylation rate of the CpG content was 77Á3% at 48 h. In the 40 lmol/l decitabine treatment group, the methylation rate of the CpG content was 72Á7% at 24 h compared with the untreated group (P < 0Á05). There was no significant difference between the VPA groups and the decitabine group (P > 0Á05) (Fig 7B) .
Results of the Co-immunoprecipitation-MS
Immunoprecipitation experiments identified 561 proteins in the experimental group and 393 identified proteins the control group. 300 proteins were detected separately in the experimental group, namely, 300 proteins interacting with the PTPN6 protein. The 300 proteins were identified by mass spectrometry, and the direct binding of HDAC1 and PTPN6 was determined. Results showed that PTPN6 protein is mainly involved in cell survival and death, protein synthesis, cell growth and proliferation, cell function and maintenance of biological processes, and is closely related with the EIF2 signalling pathway, the protein ubiquitination pathway and the cell cycle signalling pathway, CD437, RICTOR, MYC and other upstream factors associated with tumour and tissue injury and genetic diseases, and malignant haematological diseases were closely related.
Results of the ChIP-seq
After the samples were sequenced by ChIP-seq, the average output of the original reads was 27 588 525, and the net data were obtained after filtration. This showed that the PTPN6 promoter region was not directly associated with the HDAC1 protein, but the MAPK, AKT and STAT5 promoter regions were directly associated with HDAC1.
Discussion
Chronic myeloid leukaemia accounts for 15-20% of all leukaemias, and can occur in any age group. It occurs mainly in Fig 4. mRNA expression in drug-treated cell lines. The expression level of DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 mRNA decreased, and that of PTPN6 mRNA increased in a dose-dependent manner. The difference was statistically significant (P < 0Á05). *P < 0Á05 comparison among the four groups. (A) K562 cells treated with LBH589. #, D P < 0Á05 comparison between the three concentration groups. ☆, ▲ P < 0Á05 compared to 2 and 2Á5 nmol/l. (B) K562 cells treated with sodium valproate (VPA). #, ▲ P < 0Á05 comparison between the three concentration groups. D, ★ P < 0Á05 compared to 8 and 12 mmol/l. ☆, ◆ P < 0Á05 compared to 4 and 8 mmol/l. (C) K562 cells treated with 5-Azacytidine. #, ▲ P < 0Á05 compared to 20 and 40 lmol/l. D, ☆ P < 0Á05 comparison between the three concentration groups. (D) K562 cells treated with Decitabine. #, ☆ P < 0Á05 compared to 10 and 20 lmol/l. D, ▲, ★ P < 0Á05 comparison between the three concentration groups. (E) KCL22 cells treated with LBH589. #P < 0Á05 compared to 2 and 2Á5 nmol/l. D, ☆ P < 0Á05 comparison between the three concentration groups. (F) KCL22 cells treated with sodium valproate. #P < 0Á05 compared to 4 and 8 mmol/l. DP < 0Á05 compared to 8 and 12 mmol/l. ☆, ★ P < 0Á05 comparison between the three concentration groups. (G) KCL22 cells treated with 5-Azacytidine. #P < 0Á05 compared to 80 and 160 lmol/l. D, ☆, ▲, ★, ◆ P < 0Á05 comparison between the three concentration groups. (H) KCL22 cells treated with Decitabine. #P < 0Á05 compared to 10 and 20 lmol/l. D, ☆, ▲, ★, ◆ P < 0Á05 comparison between the three concentration groups. the elderly patients in China, and the proportion of male and female patients is about 3:2. CML is a clonal haematopoietic stem cell disorder in which leukaemic cells display a reciprocal t (9:22) chromosomal translocation that results in the formation of the chimeric BCR-ABL1 oncoprotein, with a constitutive tyrosine kinase activity (Deininger et al, 2000; Sonoyama et al, 2002) . Tyrosine kinase inhibitors (TKIs) have improved the 5-year survival rate of CML from 20% to 90%, but some patients still suffer disease progression and a poor prognosis (Foroni et al, 2009) . Epigenetic gene silencing plays a key role in inhibiting tumour suppressor gene expression in cancer cells (Jones & Baylin, 2002; Robertson, 2002; Herman & Baylin, 2003) .
PTPN6 is a member of the SHP protein family, cytoplasmic protein tyrosine phosphatase (PTP), and its gene has been reported to be a candidate tumour suppressor gene in lymphoma, leukaemia and other cancers (Wu et al, 2003) . PTPN6 could be a new biological indicator at baseline for imatinib sensitivity in CML patients (Esposito et al, 2011) . A retrospective study analysed 97 cDNA samples from patients with highly heterogeneous CML to assess the clinical utility of measuring PTPN6 mRNA levels in patients with CML (Kaeda et al, 2015) . Their data implied that PTPN6 plays a role in CML disease progression. Also, the hypermethylation of PTPN6 was frequently detected in several human cancers and the reduced expression of this gene mainly occurred by Column chart of the relative density of protein normalized to ACTB in K562 cells after treatment with the indicated drugs. *P < 0Á05 comparison among the five groups. #, D, ▲, ★ P < 0Á05 compared to LBH589 and decitabine. ☆ P < 0Á05 compared to sodium valproate (VPA), LBH589 and decitabine.◆ P < 0Á05 compared to LBH589, 5-Azacytidine and decitabine. (D) Column chart of the relative density of protein normalized to ACTB in KCL22 cells after treatment with the indicated drugs. *P < 0Á05 comparison among the five groups. #, ◆ P < 0Á05 compared to LBH589, VPA and decitabine. D, ☆, ▲, ★ P < 0Á05 compared to control, LBH589 and VPA. ◇, ▽ P < 0Á05 compared to VPA and 5-Azacytidine. promoter methylation in various types of leukaemias and lymphomas (Chim et al, 2004a,b; Deininger et al, 2005) . We found that in the progression of CML, the expression levels of PTPN6 mRNA and PTPN6 protein were lower than those in normal controls and CML-CP patients, while the expression level of DNMT1 and DNMT3A was lower in the patients than that in the normal controls and chronic high CML groups at the mRNA and protein levels. DNMT3B expression was not significantly different. The MSP results also confirmed that the PTPN6 gene was present in advanced CML; the promoter methylation rate was higher than in CML-CP patients and normal controls. The development phase of CML showed low PTPN6 expression relative to the methylation of the promoter region.
Gene silencing affects the gene promoter region and is executed by two principal mechanisms: methylation of DNA enriched in the CpG sequences, and modification of histones. Whereas CpG methylation is mediated by DNA methyltransferase 1 (DNMT1) and other members of the DNMT family, histone modifiers include the histone deacetylases (HDACs). MECP2 binds tightly to chromosomes in a methylationdependent manner by a transcriptional-repression domain (TRD), which can function at a distance in vitro and in vivo. A region of MECP2 that localizes with the TRD associates with a corepressor complex containing the transcriptional repressor mSin3A and histone deacetylases. DNA methylation and histone deacetylation can be linked by MECP2 (Nan et al, 1998) . MBD2 is the methyl MECP1 complex combination of the components, and this complex also includes HDAC9 (HDAC), HDAC2, RBBP7 (RbAp46), HDAC1, and RBBP4 (RbAp48) proteins, allowing MBD2 to interact with the HDAC located in the methylation of chromatin template (Feng & Zhang, 2011) .
Therefore, we determined the mRNA and protein expression level of MECP2, MBD2 and HDAC1 in CML patients, and showed that the expression levels in CML-AP and CML-BP patients were significantly higher than those in CML-CP patients and normal controls. Therefore, we believe that low PTPN6 expression level in the progression of CML is regulated by methylation and histone acetylation.
Next, we used the CML blast crisis cell lines K562 and KCL22 as a research model; the cells were treated with different concentrations of demethylation drugs (5-azacytidine and decitabine) and histone deacetylase inhibitors (VPA and LBH589). After treatment, the expression level of PTPN6 mRNA was significantly increased in K562 cells, and was negatively correlated with DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 mRNA. In KCL22 cells, the increase of PTPN6 mRNA was negatively correlated with DNMT1, MBD2 and HDAC1 mRNA, but no correlation with MECP2 mRNA. In the two cell lines, the increase of PTPN6 protein was negatively correlated with DNMT1, DNMT3A, MECP2, MBD2 and HDAC1. The difference in mRNA levels may be related to the biological characteristics of these two cell lines, in that KCL22 cells are naturally resistant cell lines that are moderately resistant to imatinib. However, similar expression levels of proteins may suggest some unknown regulatory mechanisms. CpG methylation of the PTPN6 promoter in K562 and KCL22 cells after drug treatment, detected by bisulfite sequencing polymerase chain reaction. (A) In K562 cells, there was significant difference between the sodium valproate (VPA) treatment group and the untreated group (P < 0Á05), whereas there was no significant difference between the other three groups compared with the untreated group (P > 0Á05). (B) In the KCL22 cells, the VPA group and decitabine group were significantly different compared with the control group (P < 0Á05). There was no significant difference between the VPA group and the decitabine group (P > 0Á05). There was no significant difference between the other two groups (5-Azacytidine, LBH589) compared with the untreated group (P > 0Á05).
MSP results showed that PTPN6 was methylated after treatment with each of the four drugs, though BSP results were slightly different. In the K562 cells, the decreased methylation of the PTPN6 promoter CpG after VPA treatment was statistically significant. In the KCL22 cells, after VPA and 5-Azacytidine treatment, the decline was statistically significant, but there was no statistical difference between the two drugs. Results showed that the demethylation effect of VPA was stronger than that of 5-azacytidine.
Some studies indicate that HDACs can affect the methylation of DNA. Trichostatin A can reduce the stability of DNMT3B mRNA, resulting in a decline in the level of methylation of human endometrial cancer cells (Xiong et al, 2005) . Apicidin can down regulate Hela cell DNMT1 and inhibit the DNMT1 promoter regions H3, H4 acetylation and the recruitment of Rb, HDAC1, RNA polymerase II dissociation, and trimethyl H3K7 (You et al, 2008) . In leukaemia cell lines, Trichostatin A down regulates DNMT1 mRNA. Vorinostat and panobinostat mediate HSP90 in nuclear acetylation in a breast cancer cell line, resulting in the stability of the Hsp90-DNMTl-HDAC1 complex, and further leads to the down-regulation of HDAC and DNMTl degradation (Januchowski et al, 2007) .
For further study of the regulatory mechanism of PTPN6, we performed a mass spectrometry analysis of the PTPN6 protein using immune coprecipitation and protein precipitation and found that 300 proteins bind to PTPN6 protein specifically. Only HDAC1 and the apparent protein genetic regulation directly combined with the DNA methylation and histone deacetylation of other proteins, and some did not combine with the PTPN6 protein. Then, we used ChIP-seq to detect the HDAC1 protein: the HDAC1 protein and the PTPN6 promoter region did not interact. PTPN6 gene does not play a direct role in regulating HDAC1. The promoter regions of MAPK, AKT, STAT5, JAK2, and MYC were all associated with HDAC1 protein. Therefore, we speculate that MAPK, AKT, STAT5, JAK2, MYC can regulate HDAC1, and that they can be linked to the methylation of PTPN6 gene via MECP2 and MBD2: further research is underway.
In conclusion, our studies suggest that the PTPN6 gene is associated with progression of CML. Low PTPN6 expression level is not only associated with DNA methylation, but also regulated by histone acetylation. The possible mechanism occurring is HDAC inhibitors acetylating HDAC1, which, in turn, restrains the formation of transcription complexes. The result is the failure of MBD2 and MECP2 to bind to methylated DNA, causing PTPN6 demethylation through DNMT1 and DNMT3A. VPA showed a stronger demethylation effect and provides a new way to overcome the progression of CML.
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